This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Myeloid cell surface antigen CD33.
Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine- based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:28325905, PubMed:10887109). These phosphorylations provide docking sites for the recruitment and activation of protein- tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:10556798, PubMed:10206955, PubMed:10887109).
Human | |
---|---|
Gene Name: | CD33 |
Uniprot: | P20138 |
Entrez: | 945 |
Belongs to: |
---|
immunoglobulin superfamily |
CD33 antigen (gp67); CD33 antigen; CD33 molecule; CD33; FLJ00391; gp67; myeloid cell surface antigen CD33; p67; sialic acid binding Ig-like lectin 3; Sialic acid-binding Ig-like lectin 3; Siglec3; Siglec-3; SIGLEC3gp67
Mass (kDA):
39.825 kDA
Human | |
---|---|
Location: | 19q13.41 |
Sequence: | 19; NC_000019.10 (51211054..51240016) |
Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells.
[Isoform CD33M]: Cell membrane; Single-pass type I membrane protein.; [Isoform CD33m]: Peroxisome. CD33m isoform does not localize to cell surfaces but instead accumulates in peroxisomes.
An anti-CD33 marker can be an option to consider if you are looking for a fresh treatment for blood cancer. It is a prognostic indicator and also a transmembrane receptor. It has numerous benefits. Learn more about it. In addition to its many applications, this gene plays a crucial part in a myriad of medical conditions. CD33 therapy is a great option for many reasons.
Boster Bio produces the anti-CD33 antibody. It is part of Picoband(tm). It reacts with both human and mouse CD33 proteins. It can be stored at -20°C for up to one year, or frozen for up six months. The product contains 5 mg BSA and 0.1 mg Na2HPO4 for the antigen. Boster tests the antibodies by comparing them to previously identified negative and positive samples, and then determining whether they have high affinity.
There's a new way to detect breast cancer using a genetic test known as Menacalc. Researchers discovered that this gene's expression is commonly present in the effusion of ovarian serous cancer and is elevated after chemotherapy. This is the first time Wee1 is reported as a prognostic marker independent of other indicators for serous ovarian carcinoma. This method has its limitations. Menacalc is a promising cancer biomarker that requires further research.
The CD33 gene is highly expressed in certain types of AML. Researchers have discovered that CD33 expression is linked to the survival outcomes of AML patients. They utilized flow cytometry for the evaluation of CD33 expression in bone-marrow samples taken from newly diagnosed AML patients. They utilized chi-square and t-tests to determine whether patients with low or high CD33 expression had a similar OS. They then constructed Kaplan-Meier survival curves using Cox regression models.
AML is a heterogeneous type of leukemia with poor prognosis. While the majority of patients develop acute myeloid leukemia, the majority patients have a shorter lifespan. AML is the most frequent cause of death from leukemia among adults, and has an average age of 67 years. Despite the advancements in the field, the survival rates for treated AML patients are not great. The OS rate is approximately 15 percent for adults treated with intensive cytotoxic induction chemotherapy and is even lower for patients who are or more. This is primarily due to the high relapse rate among children with this condition.
When AML cells are detected outside bloodstream, they may spread to the gums, skin and the central nervous system. A solid tumor, referred to as an extramedullary meloid leukemia can develop from the cells. These cells can develop into an AML-related solid tumor. These tumors are also known as myeloid Sarcoma, Granulocytic Sarcoma, and Chloroma. AML treatment is not standard. It is dependent on the presence of cancerous cells.
A promising target for AML targeting is the CD33 marker. CD33 is a sialic acids-binding Ig-like lectin, which displays similar expression in relapsed AML. Gemtuzumazumamicin, an anti-CD33 antibody humanized is a cytotoxic agent. It has been shown to be effective in treating AML and restoring normal hemotopoiesis.
Despite the promise of targeted therapies AML is a challenging disease to treat with single-agent medications. Because there isn't a cure for AML, drug resistance mechanisms are still an issue. A specific drug could be targeted to HSCs and treat AML. The CD33 marker could be the answer. Although the CD33 antibody is currently the only approved therapy for AML The results of clinical trials are positive and suggest a use for this approach to treat.
There are numerous biological tests that use antibodies to identify C-type lectin domain family member A (C-CRE4A). These antibodies are monoclonal or polyclonal . They react with CLEC4A in animal samples. Boster Bio produces antibodies against C-CRE4A in mice and rabbits. The gene is expressed in the peripheral blood leukocytes and neutrophils and is also expressed in the bone marrow as well as the thymus.
Antibodies against C-CRE4 have many applications in biomedical research, Boster Bio's anti-CRE4 antibody is one of the most popular. Boster provides reagents for the detection of this protein in diverse biological samples, such as microbial cultures and tissue samples. Additionally, Boster provides convenient solutions to common research and testing concerns.
PMID: 3139766 by Simmons D., et al. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells.
PMID: 11943481 by Yousef G.M., et al. Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes.